CUREVAC N.V. overview

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A hearing on infringement of EP 3 708 668 B1 is scheduled for July 1, 2025, before the Regional Court Düsseldorf Confirming validity of patent in its amended form marks major milestone in broader patent litigation in Germany, recognizing CureVac's pioneering mRNA innovation TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire /...

Issuer: CureVac / Key word(s): Patent CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE 27.03.2025 / 21:05 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent...

CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of the broadest intellectual property portfolios in mRNA technology TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / February 18, 2025 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"),...

Issuer: CureVac / Key word(s): Patent CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators 18.02.2025 / 13:03 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company...

Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028 CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNO New off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1...

Issuer: CureVac / Key word(s): Quarter Results CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update 12.11.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at 3 p.m. CET / 9 a.m. EST. Dial-in numbers to...

Issuer: CureVac / Key word(s): Quarter Results CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 07.11.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 TÜBINGEN, Germany/BOSTON, USA – November 7, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global...